Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.65 |
| ▸ | ITGA2B | P08514 | 20/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24336948 | 0.87 | ITGB3 (0.61) | ITGB3ITGA2B | |
| SCHEMBL21705409 | 0.86 | ITGB3 (0.66) | ITGB3ITGA2B | |
| SCHEMBL21706030 | 0.82 | ITGB3 (0.75) | ITGB3ITGA2B | |
| SCHEMBL26480344 | 0.81 | ITGB3 (0.65) | ITGB3ITGA2B | |
| SCHEMBL21705414 | 0.81 | ITGB3 (0.64) | ITGB3ITGA2B | |
| SCHEMBL21705407 | 0.81 | ITGB3 (0.64) | ITGB3ITGA2B | |
| SCHEMBL21705415 | 0.81 | ITGB3 (0.64) | ITGB3ITGA2B | |
| SCHEMBL21705420 | 0.80 | ITGB3 (0.63) | ITGB3ITGA2B | |
| SCHEMBL21705406 | 0.80 | ITGB3 (0.63) | ITGB3ITGA2B | |
| SCHEMBL26480347 | 0.80 | ITGB3 (0.63) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685717-B2 | Polypeptide integrin antagonists | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685717-B2 | Polypeptide integrin antagonists | ITGA2B, ITGAV, ITGB2 | ITGB3 5/4885ITGA2B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.